Sandoz, the generic drug division of Swiss drug giant Novartis, announced on 23 September 2013 the launch of a new delivery device for its biosimilar somatropin product (Omnitrope) in the UK.
Sandoz launches new device for its biosimilar somatropin
Home/Pharma News
|
Posted 27/09/2013
0
Post your comment

The device, called SurePal, aims to simplify the administration of the human growth hormone (hGH) by using cartridges that require no reconstitution or priming, and a sliding injection button that requires minimum force to operate. It also includes safety features including non-interchangeable dose-specific cartridges, a dose memory function that remembers the patient’s daily dose and a needle hider to reduce anxiety for patients afraid of needles.
In a usability study conducted by Sandoz in 106 patients in Germany and the US, 92% of respondents found an injection with SurePal very easy or easy to accomplish.
According to Mr Peter Laing, Paediatric Advanced Nurse Practitioner Endocrinology, Alder Hey Children’s NHS Foundation Trust, ‘patients treated with growth hormone therapy require an injection of hGH on a daily basis which requires significant commitment from the individual, parent or primary caregiver. Therefore, ease of use and simplicity of the growth hormone device combined with features of added patient safety are essential to ensure good treatment outcomes’.
The new device, being a Sandoz innovation, will only be available for use with the company’s biosimilar somatropin product, Omnitrope. Sandoz also intends to launch the product globally.
Related articles
EMA approves biosimilar follitropin alfa and somatropin
Sandoz to start phase III etanercept trial
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.
Source: Sandoz
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment